Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-24

Neuroprotection and natural history in parkinson plus syndromes: a clinical trial of the efficacy and safety of riluzole in parkinson plus syndromes

Objective

The Parkinson-Plus syndromes, Multiple System Atrophy and Progressive Supranuclear Palsy (MSA & PSP) are rapidly progressive neurodegenerative diseases, leading to severe disability and death. They are orphan diseases with neither symptomatic nor curative therapy. We will
(i) establish whether the antiexcitotoxic drugriluzole can slow the disease progression,
(ii) provide for the first time prospective data on their natural history. In U. K., France, and Germany, 800patients, stratified on MSA or PSP, will randomly be assigned to placebo orriluzole and followed double blind for 36 months. The primary efficacy criterionis survival.
The project will validate diagnostic staging, new assessment instruments and disease severity staging;
assess cognitive function, quality of life and health economics;
and establish DNA and tissue banks for basic research.
The project will comply with the GMP, GCP, GLP and GSP specifications.

Fields of science (EuroSciVoc)

Topic(s)

Call for proposal

Data not available

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

KING'S COLLEGE LONDON
EU contribution
No data
Address
De Crespigny Park, Denmark Hill
SE5 8AF LONDON
United Kingdom
Links
Total cost
No data

Participants (5)